

115TH CONGRESS
1ST SESSION

S. 1528

To amend the market name of genetically altered salmon in the United States, and for other purposes.

IN THE SENATE OF THE UNITED STATES

JULY 11, 2017

Ms. MURKOWSKI (for herself, Mr. SULLIVAN, Ms. CANTWELL, and Mr. MERKLEY) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the market name of genetically altered salmon in the United States, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Genetically Engineered
5 Salmon Labeling Act”.

6 **SEC. 2. PURPOSES.**

7 It is the purpose of this Act to—

8 (1) ensure that consumers in the United States
9 can make informed decisions when purchasing salm-
10 on; and

1 (2) authorize an independent scientific and
 2 technical advisory organization to conduct a review
 3 of—

4 (A) the possible effects of genetically engi-
 5 neered salmon on wild salmon stocks; and

6 (B) the Food and Drug Administration’s
 7 approval of genetically engineered salmon for
 8 human consumption.

9 **SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED**
 10 **SALMON.**

11 (a) IN GENERAL.—Notwithstanding any other provi-
 12 sion of law, for purposes of applying the Federal Food,
 13 Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the ac-
 14 ceptable market name of any salmon that is genetically
 15 engineered shall include the words “Genetically Engi-
 16 neered” or “GE” prior to the existing acceptable market
 17 name.

18 (b) DEFINITION.—For purposes of this section, salm-
 19 on is genetically engineered if it has been modified by re-
 20 combinant DNA (rDNA) techniques, including the entire
 21 lineage of salmon that contain the rDNA modification.

22 **SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON AP-**
 23 **PROVAL.**

24 (a) INDEPENDENT SCIENTIFIC ORGANIZATION RE-
 25 VIEW AND REPORT.—The Secretary of Health and

1 Human Services (referred to in this section as the “Sec-
2 retary”) shall ensure that the National Academy of
3 Sciences, or a similar independent scientific and technical
4 advisory organization, conducts a review of, and submits
5 to the Secretary a report on—

6 (1) the environmental assessment carried out by
7 the Food and Drug Administration and released on
8 November 12, 2015, in support of approval of the
9 new animal drug application under section 512 of
10 the Federal Food, Drug, and Cosmetic Act (21
11 U.S.C. 360b) with respect to AquAdvantage Salmon,
12 taking into account the impact of AquAdvantage
13 Salmon on wild stocks of salmon and related wild
14 ecosystems; and

15 (2) each environmental assessment carried out
16 by the Food and Drug Administration in support of
17 an approval of a new animal drug application under
18 section 512 of the Federal Food, Drug, and Cos-
19 metic Act (21 U.S.C. 360b) related to a genetically
20 engineered finfish intended for human consumption.

21 (b) SECOND FDA ENVIRONMENTAL ASSESSMENT.—
22 After receipt of a report under paragraph (1) or (2) of
23 subsection (a), the Secretary shall conduct a second envi-
24 ronmental assessment with respect to approval of the ap-

1 plication described in such paragraph (1) or (2), taking
2 into account the findings in such report.

3 (c) EFFECTIVE DATE OF APPROVAL.—Notwith-
4 standing any other provision of law, the approval of a new
5 animal drug application with respect to which review of
6 an environmental assessment is required under subsection
7 (a) shall not take effect until the Secretary completes a
8 second environmental assessment under subsection (b).

○